Searching News Database: metformin
HSMN NewsFeed - 16 Mar 2018
Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
HSMN NewsFeed - 10 Jan 2018
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
HSMN NewsFeed - 24 Feb 2017
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage(R) XR
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage(R) XR
HSMN NewsFeed - 30 Oct 2014
U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
HSMN NewsFeed - 19 Dec 2013
Bristol-Myers Squibb Continues Evolution to Specialty BioPharma Through Sale of Its Diabetes Business
Bristol-Myers Squibb Continues Evolution to Specialty BioPharma Through Sale of Its Diabetes Business
HSMN NewsFeed - 14 Feb 2013
Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
HSMN NewsFeed - 10 Apr 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
HSMN NewsFeed - 13 Sep 2010
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
HSMN NewsFeed - 25 Mar 2010
Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX
Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX
HSMN NewsFeed - 15 Mar 2010
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
HSMN NewsFeed - 24 Feb 2010
GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
HSMN NewsFeed - 26 Jan 2010
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
HSMN NewsFeed - 10 Nov 2009
Depomed Receives Notice of Paragraph IV Certification Against Patents for GLUMETZA(R)
Depomed Receives Notice of Paragraph IV Certification Against Patents for GLUMETZA(R)
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 29 Apr 2009
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
HSMN NewsFeed - 23 Apr 2009
U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA (saxagliptin) New Drug Application
U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA (saxagliptin) New Drug Application
HSMN NewsFeed - 26 Mar 2009
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 17 Feb 2009
GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)
GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)
HSMN NewsFeed - 25 Nov 2008
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
HSMN NewsFeed - 22 Jul 2008
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
HSMN NewsFeed - 10 Jun 2008
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
HSMN NewsFeed - 24 Mar 2008
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
HSMN NewsFeed - 14 Jan 2008
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
HSMN NewsFeed - 19 Nov 2007
Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
HSMN NewsFeed - 19 Nov 2007
Sciele Signs Exclusive Agreement with Novo Nordisk to Market Prandin(R) and PrandiMet(R)
Sciele Signs Exclusive Agreement with Novo Nordisk to Market Prandin(R) and PrandiMet(R)
HSMN NewsFeed - 29 Oct 2007
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
HSMN NewsFeed - 25 Oct 2007
Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer
Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer
HSMN NewsFeed - 17 Oct 2007
FDA Approves Supplemental New Drug Applications for JANUVIA(TM) (sitagliptin)
FDA Approves Supplemental New Drug Applications for JANUVIA(TM) (sitagliptin)
HSMN NewsFeed - 25 Sep 2007
Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
HSMN NewsFeed - 18 Sep 2007
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
HSMN NewsFeed - 27 Aug 2007
Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
HSMN NewsFeed - 20 Aug 2007
Elixir Pharmaceuticals Initiates Final Phase III Clinical Study Prior to NDA
Elixir Pharmaceuticals Initiates Final Phase III Clinical Study Prior to NDA
HSMN NewsFeed - 30 Jul 2007
SoloSTAR(R), the First Prefilled Disposable Insulin Pen for Lantus(R), is Now Available in the United States
SoloSTAR(R), the First Prefilled Disposable Insulin Pen for Lantus(R), is Now Available in the United States
HSMN NewsFeed - 10 Jul 2007
Synovics Pharmaceuticals Appoints Steven Getraer as Executive Vice President and Chief Financial Officer
Synovics Pharmaceuticals Appoints Steven Getraer as Executive Vice President and Chief Financial Officer
HSMN NewsFeed - 10 Jul 2007
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
HSMN NewsFeed - 6 Jun 2007
Statement of Moncef Slaoui, PhD, Chairman Research & Development GlaxoSmithKline
Statement of Moncef Slaoui, PhD, Chairman Research & Development GlaxoSmithKline
HSMN NewsFeed - 6 Jun 2007
Newly Published Data From Large Study Support Cardiovascular Safety of Avandia (rosiglitazone maleate)
Newly Published Data From Large Study Support Cardiovascular Safety of Avandia (rosiglitazone maleate)
HSMN NewsFeed - 30 May 2007
Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety Profile
Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety Profile
HSMN NewsFeed - 15 May 2007
Array BioPharma Appoints John Yates, MB ChB, MD, to Chief Medical Officer
Array BioPharma Appoints John Yates, MB ChB, MD, to Chief Medical Officer
HSMN NewsFeed - 24 Apr 2007
Synovics Pharmaceuticals Appoints David Coffin-Beach President and Chief Operating Officer
Synovics Pharmaceuticals Appoints David Coffin-Beach President and Chief Operating Officer
HSMN NewsFeed - 13 Apr 2007
Mylan Announces Final FDA Approval for Glipizide and Metformin Hydrochloride Tablets
Mylan Announces Final FDA Approval for Glipizide and Metformin Hydrochloride Tablets
HSMN NewsFeed - 2 Apr 2007
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
HSMN NewsFeed - 15 Feb 2007
FDA Accepts Two Supplemental New Drug Applications to Expand the U.S. Labeling for JANUVIA(TM)
FDA Accepts Two Supplemental New Drug Applications to Expand the U.S. Labeling for JANUVIA(TM)
HSMN NewsFeed - 12 Feb 2007
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology
HSMN NewsFeed - 19 Jan 2007
Barr Launches Generic METAGLIP(TM) Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg
Barr Launches Generic METAGLIP(TM) Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg
HSMN NewsFeed - 22 Dec 2006
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
HSMN NewsFeed - 21 Dec 2006
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
HSMN NewsFeed - 18 Dec 2006
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
HSMN NewsFeed - 21 Nov 2006
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
HSMN NewsFeed - 1 Nov 2006
Synovics Pharmaceuticals Initiates U.S. Development of Its Fourth Generic Oral Controlled-Release Drug
Synovics Pharmaceuticals Initiates U.S. Development of Its Fourth Generic Oral Controlled-Release Drug
HSMN NewsFeed - 14 Sep 2006
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
HSMN NewsFeed - 28 Jun 2006
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
HSMN NewsFeed - 26 Jun 2006
Wythe Therapeutics and VeroScience Announce Worldwide License for Cycloset(R)
Wythe Therapeutics and VeroScience Announce Worldwide License for Cycloset(R)
Additional items found! 148
Members Archive contains
148 additional stories matching:
metformin
(Password required)
metformin
(Password required)